Current status of treatment for esophagojejunostomy leakage after total gastrectomy in patients with gastric cancer: a multicenter retrospective study in Korea
10.7602/jmis.2025.28.4.184
- Author:
Min-Chan KIM
1
;
Mi Ran JUNG
;
Jeong Ju NOH
;
Sunghwa KANG
;
Jae Hun CHUNG
;
Ji-Ho PARK
;
Tae-Han KIM
;
Jae Kyun PARK
;
Yoonhong KIM
;
Sang Hyuk SEO
;
Sung Eun KIM
;
Oh Kyung KWON
;
Ji Yeon PARK
;
Ki Bum PARK
;
Sun-Hwi HWANG
;
SI-Hak LEE
;
Young-Joon LEE
;
Sang-Ho JEONG
;
Tae-Yong JEON
;
Dae Hwan KIM
;
Chang In CHOI
;
Ki Young YOON
;
Kyung Won SEO
;
Ki Hyun KIM
;
Sang Hoon OH
;
Kwang Hee KIM
Author Information
1. Department of Surgery, Dong-A University College of Medi- cine, Busan, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Minimally Invasive Surgery
2025;28(4):184-192
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Esophagojejunostomy leakage (EJL) remains one of the most critical complications following total gastrectomy for gastric cancer. This study aimed to evaluate the evolving therapeutic approaches and clinical outcomes of EJL using data from a large-scale multicenter retrospective cohort.
Methods:Among 6,577 patients who underwent total gastrectomy or proximal gastrectomy with double tract reconstruction at nine institutions from 2003 to 2024, 196 (3.0%) developed EJL. Of these, 162 patients with comprehensive clinical data were included in the final analysis. The study examined treatment modalities, changes in management over time, patient characteristics, surgical variables, and clinical outcomes. Four groups were defined according to treatment approach: conservative, endoscopic, reoperation, and multimodal (combined) therapy.
Results:Endoscopic therapy was first introduced in 2011 and has progressively supplanted reoperation, now comprising 32.5% of cases. The average time to EJL diagnosis was 8.4 days after surgery. Overall in-hospital mortality was 6.1% (10/162). When conservative management was excluded, endoscopic treatment demonstrated the highest rate of therapeutic success (94.3%, p = 0.004). Both the duration until diet resumption and length of hospital stay were notably reduced in the endoscopic and conservative groups compared with reoperation and multimodal therapy (p < 0.001). Moreover, although the highest post-leakage hospitalization costs were observed with multimodal treatment (p < 0.001), overall hospitalization expenses were significantly lower for patients managed conservatively or with endoscopic intervention (p < 0.001).
Conclusion:Over the past two decades, management of EJL has shifted toward endoscopic approaches. Endoscopic therapies yield superior clinical outcomes and should be considered a primary option for appropriate candidates.
